European equities traded in the US as American depositary receipts were slightly higher late Thursday morning, edging 0.10% higher to 1,298.82 on the S&P Europe Select ADR Index.
From continental Europe, the gainers were led by furniture maker Natuzzi (NTZ) and medical device maker EDAP TMS (EDAP), which climbed 18% and 7.3% respectively. They were followed by telecommunications company VEON (VEON) and biopharmaceutical company Genfit (GNFT), which were up 2.5% each.
The decliners from continental Europe were led by biotech firm Evaxion Biotech (EVAX) and biopharmaceutical company DBV Technologies (DBVT), which dropped 2.8% and 2.6% respectively. They were followed by accommodations booking company trivago (TRVG) and 3D printer company Materialise (MTLS), which were off 0.7% each.
From the UK and Ireland, the gainers were led by biotech firm Autolus Therapeutics (AUTL) and biopharmaceutical company Verona Pharma (VRNA), which increased 2.2% and 2% respectively. They were followed by biopharmaceutical companies Bicycle Therapeutics (BCYC) and TC Biopharm (TCBP), which rose 1.8% and 1% respectively.
The decliners from the UK and Ireland were led by biopharmaceutical company Adaptimmune Therapeutics (ADAP) and biotech firm Trinity Biotech (TRIB), which dropped 3.8% and 3% respectively. They were followed by biopharmaceutical company Akari Therapeutics (AKTX) and pharmaceutical company Silence Therapeutics (SLN), which lost 1.6% and 1.5% respectively.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。